Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | JAK3 | P52333 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | NCK1 | P16333 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494575 | 0.78 | LCK (1.00) | BACE1CTSDLCKKDRJAK3 | |
| SCHEMBL22926832 | 0.78 | BACE1 (1.00) | BACE1CTSDNCK1PLAUNCF1 | |
| SCHEMBL9826 | 0.77 | BACE1 (0.62) | BACE1CTSDNCF1ACHE | |
| SCHEMBL5478956 | 0.77 | BACE1 (0.62) | BACE1CTSDNCK1PLAUNCF1 | |
| SCHEMBL14244867 | 0.76 | ABL1 (0.69) | BACE1CTSDLCKKDRJAK3 | |
| SCHEMBL9711 | 0.76 | BACE1 (0.61) | BACE1CTSDPLAUNCF1NOS2 | |
| SCHEMBL5157768 | 0.75 | CTSD (0.60) | BACE1CTSDLCKKDRJAK3 | |
| SCHEMBL3155647 | 0.75 | CTSD (0.59) | BACE1CTSDLCKKDRJAK3 | |
| SCHEMBL9932 | 0.75 | BACE1 (0.59) | BACE1CTSDJAK3ACHE | |
| SCHEMBL15598665 | 0.74 | BACE1 (0.59) | BACE1CTSDLCKKDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822485-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2504330-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063272-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885CTSD 828/4885LCK 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.